- | Xalud Pharmaceuticals
What key indicators do you look at to predict the future of this industry?
At Xalud, we’re developing a non-viral plasmid DNA platform that has the potential to change the paradigm in chronic inflammatory diseases by creating a gene therapy for the masses and not just for rare diseases. We have a pipeline with broad potential for our proprietary platform, including several programs in development, and we look forward to being part of this new wave in gene therapy.
- | Alto Neuroscience
Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds
But in 2019, he walked away from all of that to become the founder and CEO of Alto Neuroscience, which the company said is “pioneering an approach to psychiatric drug development which matches the right patient with the right Alto drug based on AI-derived brain biomarkers.”
- | Teclison
Triggering a Systemic Immune Response Against Cancer
Teclison has developed platform technology that chokes off tumors and activates the immune system against the cancer.
- | Check-Cap
Lessons in Leadership — Building a Successful Team and Checking Your Ego at the Door: Interview with Check-Cap Founder and CTO Yoav Kimchy
That’s why Yoav Kimchy, Founder and CTO of Check-Cap, launched the company in 2005 with the goal of creating a technology that could make colorectal screenings easier and less invasive for patients.
- | BlueSphere Bio
TCRs as Guidance Systems in Cancer Immunotherapy
“We’ve hit the wall in terms of how much more we can leverage an antibody,” says David Apelian, MD, PhD. As the CEO of BlueSphere Bio, Apelian is more than willing to consider alternatives to antibodies. Indeed, BlueSphere is interested in developing therapies that rely on T-cell receptors (TCRs). The company is already using TCR technology to seize opportunities presented by blood-based and solid tumors.
- | Araris Biotech
Araris Biotech AG Nabs $24M to Bring ADC, Linker Programs to Clinic
Araris Biotech AG secured $24 million in financing to advance the development of its proprietary antibody-drug conjugate-linker technology and drive its own ADC candidates into the clinic.
- | IMV
PLATFORM TECHNOLOGY – The Evolution of Cancer Vaccines: Moving Beyond Failure & a New Era for Cancer Treatment
IMV is evaluating DPX-based assets in several clinical trials in difficult-to-treat cancer indications, including diffuse large B-cell lymphoma (DLBCL), ovarian, breast, and bladder cancer. Previous studies have shown encouraging results, notably in patients who have failed on prior lines of therapy. MVP-S is the clinical validation and proof of concept of the DPX platform’s potential in hematologic and solid cancer indications with and without CPIs.
- | AltruBio, Inc.
Focus on Fill and Finish
“Continued innovation in both conventional and next-generation protein therapeutics, cell and gene therapies, RNA- and DNA-based treatments, and vaccine technologies is driving demand for fill/finish capacity,” says Ping-Yang Yeh, president of AltruBio Taiwan, a subsidiary of AltruBio, Inc.
